First step for new fatty liver drug: safety check in healthy volunteers
Knowledge-focused
Completed
This was an early-stage safety study for a potential new medicine called ACT500, which is being developed for a serious liver condition called non-alcoholic steatohepatitis (NASH). The study tested single and multiple doses in 72 healthy Chinese adults to see how safe the drug wa…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC